The global biomarkers market size reached US$ 56.78 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 124.05 Billion by 2027, exhibiting a growth rate (CAGR) of 12.70% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Biomarkers, also known as biological markers, are molecules or genes that are used as indicators of the health or status of an organ, tissue, or cell. In addition to blood and bodily fluids, biomarkers are also found in tissues. In the discovery and development of new drugs, biomarkers are used for risk assessment, molecular diagnostics, disease diagnosis, DNA fingerprinting, and eliminating complexity. As a result, they play a crucial role in improving the drug development process, drug validation and testing, sample preparation and assay development. Biomarkers are often integrated with key imaging technologies that can provide clear images of oncology tumors and other problems while also eliminating the possibility of radiation exposure during CT scans and MRI scans.

Biomarkers Market Trends:
The market is majorly driven by the rising incidences of numerous chronic diseases among the masses, particularly in the geriatric population. In addition to this, the increasing implementation of biomarkers in infectious disease diagnosis is propelling the market. Moreover, continual developments in biomarker-based diagnostics, such as biomarker signatures resulting in faster drug development, non-invasive testing, and early diagnosis, are also creating a positive market outlook. In line with this, the rapid utilization of biomarkers in the development of companion diagnostics to identify drug target molecules is providing an impetus to the market. Also, the escalating demand for personalized medicine, along with a paradigm shift toward biomarker studies from conventional pathophysiology and epidemiology methods, is fueling the market. Furthermore, a considerable rise in the number of contract research organizations facilitating cost-efficient clinical trials are creating a positive market outlook. Some of the other factors contributing to the market include extensive research and development (R&D) activities and the increasing medical expenditure.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global biomarkers market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, type, disease, application and end user.

Breakup by Product:

Consumables
Services
Software

Breakup by Type:

Efficacy Biomarkers
Safety Biomarkers
Validation Biomarkers

Breakup by Disease:

Cancer
Cardiovascular Disorders
Neurological Disorders
Immunological Disorders
Renal Disorders
Others

Breakup by Application:

Diagnostics
Drug Discovery and Development
Personalized Medicine
Others

Breakup by End User:

Pharmaceutical and Biotechnology Companies
Diagnostic and Research Laboratories
Hospitals and Specialty Clinics
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Bio-Rad Laboratories Inc., Charles River Laboratories International Inc., Epigenomics AG, Eurofins Scientific SE, Merck KGaA, Perkinelmer Inc., Qiagen N.V, Quanterix Corporation, SphingoTec GmbH and Thermo Fisher Scientific Inc.

Key questions answered in this report:
How has the global biomarkers market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global biomarkers market?
What are the key regional markets?
What is the breakup of the market based on the product?
What is the breakup of the market based on the type?
What is the breakup of the market based on the disease?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global biomarkers market and who are the key players?
What is the degree of competition in the industry?